Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LEGN NASDAQ:MIRM NASDAQ:RYTM NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLEGNLegend Biotech$33.52+0.4%$27.27$16.24▼$45.30$6.20B0.352.72 million shs1.05 million shsMIRMMirum Pharmaceuticals$102.04+0.5%$98.29$47.89▼$114.99$6.19B0.5647,739 shs1.97 million shsRYTMRhythm Pharmaceuticals$95.83+6.8%$88.27$60.70▼$122.20$6.15B1.91598,797 shs1.74 million shsURGNUrogen Pharma$32.81+2.7%$26.51$12.73▼$33.40$1.56B1.59613,274 shs547,645 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLEGNLegend Biotech-5.92%-0.33%+21.16%+83.31%-6.86%MIRMMirum Pharmaceuticals+0.54%+6.36%-0.62%+10.79%+101.41%RYTMRhythm Pharmaceuticals+0.02%+2.12%-0.88%+4.50%+43.81%URGNUrogen Pharma+3.53%+13.38%+11.01%+72.89%+122.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLEGNLegend Biotech$33.52+0.4%$27.27$16.24▼$45.30$6.20B0.352.72 million shs1.05 million shsMIRMMirum Pharmaceuticals$102.04+0.5%$98.29$47.89▼$114.99$6.19B0.5647,739 shs1.97 million shsRYTMRhythm Pharmaceuticals$95.83+6.8%$88.27$60.70▼$122.20$6.15B1.91598,797 shs1.74 million shsURGNUrogen Pharma$32.81+2.7%$26.51$12.73▼$33.40$1.56B1.59613,274 shs547,645 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLEGNLegend Biotech-5.92%-0.33%+21.16%+83.31%-6.86%MIRMMirum Pharmaceuticals+0.54%+6.36%-0.62%+10.79%+101.41%RYTMRhythm Pharmaceuticals+0.02%+2.12%-0.88%+4.50%+43.81%URGNUrogen Pharma+3.53%+13.38%+11.01%+72.89%+122.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLEGNLegend Biotech 2.67Moderate Buy$60.2379.69% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$139.8037.01% UpsideRYTMRhythm Pharmaceuticals 2.83Moderate Buy$133.1338.92% UpsideURGNUrogen Pharma 2.86Moderate Buy$39.5020.39% UpsideCurrent Analyst Ratings BreakdownLatest URGN, LEGN, MIRM, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026RYTMRhythm Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/16/2026RYTMRhythm Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$143.00 ➝ $151.006/15/2026RYTMRhythm Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$133.006/15/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/15/2026RYTMRhythm Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$144.00 ➝ $155.006/15/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/15/2026MIRMMirum Pharmaceuticals CLSASubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$146.006/15/2026MIRMMirum Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$140.00 ➝ $146.006/11/2026MIRMMirum Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$140.00 ➝ $150.006/8/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)6/3/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLEGNLegend Biotech$1.03B6.05N/AN/A$5.43 per share6.17MIRMMirum Pharmaceuticals$521.31M11.94$0.05 per share1,991.99$6.12 per share16.67RYTMRhythm Pharmaceuticals$189.76M34.61N/AN/A$2.08 per share46.07URGNUrogen Pharma$109.79M14.56N/AN/A($2.25) per share-14.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLEGNLegend Biotech-$296.80M-$0.68N/A18.52N/A-21.98%-24.92%-14.87%8/10/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$13.61N/A443.65N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)RYTMRhythm Pharmaceuticals-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%8/4/2026 (Estimated)URGNUrogen Pharma-$153.49M-$2.75N/A23.44N/A-94.83%N/A-62.85%8/6/2026 (Estimated)Latest URGN, LEGN, MIRM, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026LEGNLegend Biotech-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million5/7/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLEGNLegend BiotechN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLEGNLegend BiotechN/A2.132.05MIRMMirum Pharmaceuticals1.282.091.99RYTMRhythm PharmaceuticalsN/A4.173.89URGNUrogen PharmaN/A4.694.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLEGNLegend Biotech70.89%MIRMMirum PharmaceuticalsN/ARYTMRhythm PharmaceuticalsN/AURGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipLEGNLegend Biotech0.02%MIRMMirum Pharmaceuticals8.32%RYTMRhythm Pharmaceuticals5.90%URGNUrogen Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLEGNLegend Biotech2,965185.74 million185.70 millionOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionableRYTMRhythm Pharmaceuticals14068.53 million64.49 millionOptionableURGNUrogen Pharma20048.72 million46.38 millionOptionableURGN, LEGN, MIRM, and RYTM HeadlinesRecent News About These CompaniesIs UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?June 14 at 11:14 AM | fool.comGuggenheim Remains a Buy on Urogen Pharma (URGN)June 10, 2026 | theglobeandmail.comUroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comMark Schoenberg Sells 5,222 Shares of Urogen Pharma (NASDAQ:URGN) StockJune 10, 2026 | insidertrades.comUrogen Pharma (NASDAQ:URGN) Given Average Rating of "Moderate Buy" by BrokeragesJune 9, 2026 | americanbankingnews.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comUroGen settles with Teva over Jelmyto patent disputeJune 3, 2026 | msn.comUroGen, Teva Settle Jelmyto Patent Dispute, License GenericJune 2, 2026 | tipranks.comUroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solutionJune 2, 2026 | globenewswire.comUroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 1, 2026 | globenewswire.comWhat to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock SurgeMay 24, 2026 | aol.comAHow UGN-103’s Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) InvestorsMay 23, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN) and CervoMed (CRVO)May 18, 2026 | theglobeandmail.comUroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer TranscriptMay 17, 2026 | seekingalpha.comUroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBCMay 15, 2026 | globenewswire.comUroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION TrialMay 13, 2026 | globenewswire.comURGN Share News TodayMay 12, 2026 | uk.investing.comUrogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?May 11, 2026 | zacks.comAssessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch MomentumMay 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026URGN, LEGN, MIRM, and RYTM Company DescriptionsLegend Biotech NASDAQ:LEGN$33.52 +0.14 (+0.42%) Closing price 04:00 PM EasternExtended Trading$31.29 -2.23 (-6.65%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Mirum Pharmaceuticals NASDAQ:MIRM$102.04 +0.49 (+0.48%) Closing price 04:00 PM EasternExtended Trading$102.04 +0.00 (+0.00%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Rhythm Pharmaceuticals NASDAQ:RYTM$95.83 +6.11 (+6.81%) Closing price 04:00 PM EasternExtended Trading$97.78 +1.95 (+2.03%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Urogen Pharma NASDAQ:URGN$32.81 +0.86 (+2.69%) Closing price 04:00 PM EasternExtended Trading$32.77 -0.04 (-0.12%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Insider Sales Look Big, But Should Investors Worry? Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
